[{"from": "human", "value": "Provide a description of this molecule. [C][C@@H1][Branch2][Ring2][N][C][=C][C][=C][Branch2][Ring1][Branch1][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][C][#C][C][=C][N][Branch1][Branch1][N][=C][Ring1][Branch1][C][C][=Branch1][C][=O][N][Ring2][Ring1][Ring1][C][=C][C][=C][C][=C][Ring1][=Branch1][N][C][=Branch1][C][=O][C][=C][N][=C][C][=C][N][Ring1][=Branch1][N][=C][Ring1][=Branch2][N]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable, highly selective small molecule inhibitor of the gamma isoform of phosphoinositide-3 kinase (PI3K-gamma) with potential immunomodulating and antineoplastic activities. Upon administration, eganelisib prevents the activation of the PI3K-gamma-mediated signaling pathways, which may lead to a reduction in cellular proliferation in PI3K-gamma-expressing tumor cells. In addition, this agent is able to modulate anti-tumor immune responses and inhibit tumor-mediated immunosuppression. Unlike other isoforms of PI3K, the gamma isoform is overexpressed in certain tumor cell types and immune cells; its expression increases tumor cell proliferation and survival. By selectively targeting the gamma isoform, PI3K signaling in normal, non-neoplastic cells is minimally or not affected, which results in a reduced side effect profile."}]